Plain-English translation of NCT03110562 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compared two treatment approaches for multiple myeloma—a blood cancer—in people whose disease had returned or stopped responding to earlier therapy. One group received combined with two other medications ( and ), while the other group received just the two standard medications without . The study examined whether adding this new medication helped people live longer and feel better.
Multiple myeloma often comes back or becomes resistant to initial treatment, leaving patients with limited options. Researchers wanted to know whether this newer medication could work better than standard therapy alone when cancer has become hard to treat.
Participants were randomly assigned to receive either the three-drug or two-drug treatment combination. Those in the new three-drug group received as tablets once weekly by mouth, plus weekly injections of and twice-weekly oral doses, continuing in 35-day cycles until the cancer progressed or side effects became unmanageable. Those assigned to standard treatment received injections and tablets in 21-day cycles for the first 8 cycles, then continued on a modified schedule. Participants had regular clinic visits for blood tests, physical exams, and monitoring of how well the treatment was working.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States